000			04150nam a2200457 i 4500
999			_c382706 _d382706
001			382706
003			ES-MaUEC
005			20230102122006.0
006			a|||| o|||| 00| 0
007			cr nn 008mamaa
008			220307s2022 sz | o |||| 0|eng d
020			_a9783030833954
024	7		_a10.1007/978-3-030-83395-4 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRS199.5 _b2022 EB
245	0	0	_aPharmacokinetics and Pharmacodynamics of Nanoparticulate Drug Delivery Systems _cedited by Jayvadan K. Patel, Yashwant V. Pathak
250			_a1st edition 2022
264		1	_aCham _bSpringer International Publishing _c2022
300			_a1 recurso en línea (XIII, 438 páginas) _b102 ilustraciones, 84 ilustraciones a color
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_aarchivo de texto _bPDF
505	0		_aPart 1-Modelling of PK/PD for NPDDS -- Introduction to Nanoparticulate Drug Delivery Systems -- Nanoparticle Properties Affecting Pharmacokinetics of NPDDS -- Models Used for Biopharmaceutical Evaluation of NPDDS -- Models Used in the Pharmacokinetic Evaluation of NPDDS -- Models Used in the Pharmacodynamic Evaluation of NPDDS -- Preclinical Animal Models For Experimental Design of Pharmacokinetic Studies of NPDDS -- Pharmacokinetic Modelling Program (PKMP) -- Part 2-PK/PD for Specific Nanocarriers -- Pharmacokinetic and Pharmacodynamics of Liposomal Nanoparticles -- Pharmacokinetics of Polymer Matrix Drugs (NPDDS) -- Pharmacokinetics of Long-Circulating NPDDS -- Metallic Gold Nanoparticles in vivo Pharmacokinetics and X-ray Contrast imaging Studies -- Muco-adhesive NPDDS In Vitro and Pharmacokinetics Studies -- Pharmacokinetic and Tissue Distribution Study of Solid Lipid Nanoparticles -- Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles -- PKPD of PLGA-PEG-PLGA Triblock CoPolymeric Micelles -- Part 3-PKPD in Diseased Conditions for NPDDS -- Bridging Bio-Nanoscience and Cancer Nanomedicine -- Clearance Pathways and Tumor Targeting of Imaging Nanoparticles for Diagnostics -- PLGA Nanoparticles for Oral Delivery-Nephrotoxicity and Pharmacokinetic Studies -- Pharmacokinetics of Nanoparticle Systems for Pulmonary Delivery -- In vivo Biodistribution and Pharmacokinetic Studies of NPDDS for Brain Targeting -- Enhanced Bioavailability and Intestinal Uptake Nanoparticles After Oral Delivery -- Nanoparticle Pharmacokinetic Profiling In Vivo Using Magnetic Resonance Imaging.
520			_aA reference is needed that addresses the recent progress in aspects of PK/PD methods and developments of nanoparticles for novel drug delivery systems. No other consolidated published reference discusses the PK/PD study of nanoparticle drug delivery systems. This book discusses the advantages of nanoparticle drug delivery systems (NPDDS) in enhancing the pharmacokinetics of many drugs that are not easily metabolized or that obtain the desired therapeutic effect with minimum toxicity. The authors provide an overview of biodistribution with a focus on polymer and lipid nanoparticles. This thorough reference is divided into three parts: Modelling, Specific carries and their potential to treat specific diseases.
988			_aSpringer_BiomedLife_2022
650		7	_2embne _9667667 _aSistemas de liberación de fármacos
650		7	_2embne _9445593 _aNanomedicina
700	1		_aPatel, Jayvadan K. _eeditor literario
700			_aPathak, Yashwant V. _eeditor literario _9683890
773	0		_tSpringer Nature eBook
776	0	8	_iPrinted edition: _z9783030833947
776	0	8	_iPrinted edition: _z9783030833961
776	0	8	_iPrinted edition: _z9783030833978
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-83395-4 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b09/2022 _dz _eb _zSI